Status:
COMPLETED
Fractional Laser Assisted Delivery of Sculptra® for the Treatment of Striae
Lead Sponsor:
Henry Ford Health System
Collaborating Sponsors:
Galderma R&D
Conditions:
Striae Distensae
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This study evaluates the efficacy of treatment of striae distensae using the combined modality of fractional laser and poly-L lactic acid (Sculptra).
Detailed Description
Striae Distensae (SD) is a form of scarring that can oftentimes be quite disfiguring and emotionally distressing to individuals. Fractional laser therapy has been used by doctors to treat stretch mar...
Eligibility Criteria
Inclusion
- Subject has bilateral striae alba
- Subject has stable body weight for at least 6 months with Fitzpatrick skin type 1-4
Exclusion
- Subject has striae rubra
- Pregnant
- History of adverse effects to phototherapy
- Subject has single sided lesions
- Subject has immunosuppression
- Subject has radiation therapy to the study area
- Subject has topical or oral steroid use or chemotherapy within the last 6 months
- History of keloids or hypertrophic scar
Key Trial Info
Start Date :
July 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03858543
Start Date
July 15 2019
End Date
January 31 2021
Last Update
August 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Health System
Detroit, Michigan, United States, 48202